Sanviva brings together medical device distributors Apodan, PartnerMed, AllweCare and XboXLab, operating across the Nordics and Benelux with a portfolio covering product categories such as wound care, ostomy care and in vitro diagnostics. The network is built on longstanding exclusive supplier relationships, a strong local presence, and expertise in regulatory requirements and public tenders. Together, the Sanviva network helps suppliers bring medical devices to healthcare markets throughout Europe. Sanviva currently employs around 60 people across Denmark, Sweden, Norway, Finland, Belgium and the Netherlands.

“We invested in Sanviva to combine local expertise with broader European reach,” says Jacob Drakenberg Walberg, Partner at Axcel. “We will continue to expand the product portfolio and geographic presence of Sanviva, building a pan-European distribution platform that provides medical device suppliers with access to multiple markets through a single network of trusted local partners.”

Andreas von Scholten joins Sanviva as Group CEO
Andreas von Scholten has been appointed Group CEO of Sanviva. He is joining the network from Grobest Group and has previously held senior leadership roles at Zoetis and Coloplast.

“We believe that local presence and deep market understanding are essential to serving our suppliers and customers,” says Andreas von Scholten. “Many medical device developers prefer to work with trusted local partners rather than build their own presence in every country. Through exclusive relationships, suppliers benefit from local expertise and established relationships without having to navigate each market separately, while healthcare providers and patients gain access to the latest innovations.”

Axcel Elevate I continues its deployment
The investment in Sanviva was made through Axcel Elevate I, Axcel’s lower mid-market fund focused on technology, business services and healthcare. The transaction was completed in March 2026.

The Axcel Elevate strategy builds on Axcel’s firm roots in the Nordic lower mid-market and complements the firm’s larger funds. The EUR 459m fund closed in November 2025 and has so far invested in Sanviva and Norwegian fintech company KapitalKontroll.